France enlists EU help to squeeze Sovaldi drug price
This article was originally published in SRA
Executive Summary
In a move that could signal closer collaboration among European drug pricing authorities, France has secured the support of more than a dozen other EU countries in an effort to bring down the cost of Gilead's hepatitis C drug Sovaldi (sofosbuvir) and other hepatitis drugs.